Bulk Pharmaceutical API Sources for ISTODAX

Bulk Pharmaceutical API Sources for ISTODAX

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-15149
AbaChemScene		CS-0985
Molport		MolPort-035-395-708
Hello Bio		HB1386
Clearsynth		CS-T-61146
AbovChem LLC		HY-15149

ISTODAX API Sourcing Landscape

Last updated: February 19, 2026

This analysis details bulk active pharmaceutical ingredient (API) sourcing for ISTODAX (romidepsin), focusing on key manufacturers, supply chain considerations, and patent exclusivity.

What is ISTODAX (romidepsin)?

ISTODAX is a histone deacetylase (HDAC) inhibitor used in the treatment of peripheral T-cell lymphoma (PTCL). Its active pharmaceutical ingredient is romidepsin, a cyclic peptide. Romidepsin was developed by Astex Pharmaceuticals and is marketed by Bristol Myers Squibb in the United States.

Key API Manufacturers for Romidepsin

Romidepsin is a complex molecule requiring specialized manufacturing capabilities. Sourcing typically involves contract manufacturing organizations (CMOs) with expertise in peptide synthesis and fermentation.

• Existing Manufacturers: Information on specific commercial manufacturers of romidepsin API is proprietary and not publicly disclosed by the marketing authorization holder. However, companies with advanced capabilities in complex peptide synthesis and small-scale fermentation are potential candidates for supplying such an API. These include companies that specialize in oncology drug APIs.
• Geographic Concentration: API manufacturing for complex molecules like romidepsin is often concentrated in regions with established pharmaceutical manufacturing infrastructure and regulatory compliance, primarily North America, Europe, and select Asian countries (e.g., India, China) with advanced biopharmaceutical capabilities.
• Regulatory Compliance: Any API manufacturer must adhere to Good Manufacturing Practices (GMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Supply Chain and Logistics

The supply chain for a niche oncology API like romidepsin is characterized by:

• Specialized Storage and Handling: Romidepsin, as a cytotoxic agent, requires specific handling protocols to ensure safety and maintain product integrity. This includes temperature-controlled storage and transport.
• Batch Size and Lead Times: Production campaigns for such specialized APIs are typically conducted in smaller, controlled batches. Lead times can be significant due to complex synthesis steps and the need for rigorous quality control.
• Quality Control and Assurance: Robust quality control measures are essential at every stage of the API manufacturing process, from raw material sourcing to final product release. This involves extensive analytical testing to confirm identity, purity, and potency.

Patent Exclusivity and Generic Competition

The patent landscape for ISTODAX and its API, romidepsin, significantly influences market dynamics and API sourcing strategies.

• Orphan Drug Designation: Romidepsin has received Orphan Drug Designation in both the U.S. and Europe for the treatment of PTCL. This designation provides market exclusivity for a period of seven years in the U.S. and ten years in Europe from the date of approval for a specific orphan indication.
• Key Patents:
  • Composition of Matter Patents: The primary patent protecting romidepsin itself would have been granted early in the drug's development. For romidepsin, this would likely have expired or be nearing expiration. U.S. Patent 5,001,132, for example, covers certain depsipeptides including romidepsin, and was filed in 1988 and granted in 1991, indicating its expiration in 2008 [1].
  • Method of Use Patents: Patents covering specific therapeutic uses, dosages, or formulations of romidepsin may extend market exclusivity.
  • Process Patents: Patents related to novel or improved manufacturing processes for romidepsin API can also provide a degree of protection.
• Market Exclusivity vs. Patent Expiration: While orphan drug exclusivity is a significant factor, the expiration of composition of matter patents is critical for the entry of generic competitors.
• Generic Entry Timelines: The absence of specific information on process patents or late-stage method-of-use patents suggests that the primary period of market exclusivity is tied to the orphan drug designation and the initial patent expiry. Generic competition for romidepsin API is contingent on these exclusivity periods and the ability of generic manufacturers to develop bioequivalent products and navigate regulatory approvals.

Potential API Sourcing Strategies for Generic Manufacturers

For companies seeking to enter the romidepsin API market post-exclusivity, the following strategies are relevant:

1. CMO Identification and Qualification:

   • Specialized Peptide Synthesis: Engage CMOs with demonstrated expertise in complex cyclic peptide synthesis and large-scale fermentation.
   • Regulatory Track Record: Prioritize CMOs with a history of successful FDA and EMA inspections and GMP compliance.
   • Cost-Effectiveness: Balance manufacturing expertise with cost efficiency, considering the potential for price competition in a generic market.
   • Capacity and Scalability: Ensure the CMO can scale production to meet anticipated market demand.

2. Process Development and Optimization:

   • Non-Infringing Synthesis Route: Develop or acquire a synthesis route that does not infringe upon any existing, unexpired process patents.
   • Cost Reduction: Optimize the synthesis process to reduce raw material costs, improve yields, and minimize waste.
   • Analytical Method Development: Establish robust analytical methods for API characterization and quality control, ensuring compliance with pharmacopoeial standards.

3. Regulatory Filing Support:

   • Drug Master File (DMF): Prepare and file a comprehensive DMF with regulatory authorities, detailing the API manufacturing process, quality controls, and facility information.
   • Bioequivalence Studies: Conduct necessary bioequivalence studies for the finished drug product to support marketing authorization applications.

Table 1: Romidepsin API Manufacturing Considerations

Factor	Description
Chemical Class	Cyclic peptide
Therapeutic Area	Oncology (Peripheral T-cell Lymphoma)
Manufacturing Complexity	High; requires specialized peptide synthesis and fermentation capabilities.
Key Process Steps	Fermentation, chemical synthesis, purification, cyclization.
Regulatory Oversight	Strict adherence to cGMP guidelines (FDA, EMA).
Quality Control	Rigorous testing for identity, purity, potency, impurities, and stability.
Handling Precautions	Cytotoxic nature necessitates specialized containment and safety protocols.
API Supplier Landscape	Dominated by specialized CMOs with advanced peptide synthesis and fermentation expertise.
Supply Chain Risks	Reliance on single-source suppliers, long lead times, stringent quality requirements.
Intellectual Property	Expiration of core composition of matter patents is a key driver for generic API sourcing.

Key Takeaways

• Romidepsin API manufacturing is highly specialized, relying on CMOs with advanced peptide synthesis and fermentation expertise.
• Regulatory compliance and stringent quality control are paramount for API suppliers.
• The expiration of romidepsin's core composition of matter patents and orphan drug exclusivity periods will dictate the entry of generic API manufacturers.
• Generic API sourcing strategies must focus on identifying qualified CMOs, developing non-infringing synthesis routes, and supporting regulatory filings.

FAQs

1. Who are the primary commercial manufacturers of ISTODAX (romidepsin) API currently? Specific commercial manufacturers are proprietary and not publicly disclosed by the marketing authorization holder. Sourcing is typically through specialized contract manufacturing organizations (CMOs).

2. What is the typical lead time for manufacturing a batch of romidepsin API? Lead times for complex APIs like romidepsin are generally significant, often ranging from several months to over a year, due to intricate synthesis steps and quality control processes.

3. Are there any known process patents that could hinder generic romidepsin API manufacturing? Detailed analysis of all active process patents related to romidepsin synthesis is required by potential generic manufacturers. Publicly available information does not broadly disclose specific, unexpired process patents that would universally block all generic API production routes.

4. What are the key quality attributes that must be controlled for romidepsin API? Key quality attributes include identity, purity (e.g., absence of related substances and residual solvents), potency, chiral purity, and stability under specified storage conditions.

5. How does the orphan drug designation for romidepsin affect API sourcing for generic products? Orphan drug designation provides market exclusivity for a specified period (seven years in the U.S., ten in Europe). API sourcing for generic products can only commence in earnest after this exclusivity period, or upon resolution of any other market protection mechanisms, has ended.

Citations

[1] U.S. Patent 5,001,132 (1991). Depsipeptides. Issued April 16, 1991.